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Meta-analysis of MTHFR 677C→T polymorphism and coronary
heart disease: does totality of evidence support causal role for
homocysteine and preventive potential of folate?
Sarah J Lewis, Shah Ebrahim, George Davey Smith
Abstract
Objectives To investigate the association between the MTHFR
677C→T polymorphism and coronary heart disease, assessing
small study bias and heterogeneity between studies.
Data sources Medline and Embase citation searches between
January 2001 and August 2004; no language restrictions.
Study selection Case-control and prospective studies of
association between MTHFR 677C→T variant and myocardial
infarction, coronary artery occlusion, or both; 80 studies were
included.
Data extraction Data on genotype frequency and mean
homocysteine concentrations by genotype were extracted. Odds
ratios were calculated for TT genotype versus CC genotype.
Heterogeneity was explored, with stratification by geographical
region of the study samples, and meta-regression by difference
in mean serum homocysteine concentrations (CC minus TT
genotypes) was carried out.
Results 26 000 cases and 31 183 controls were included. An
overall random effects odds ratio of 1.14 (95% confidence
intervals 1.05 to 1.24) was found for TT versus CC genotype.
There was strong evidence of heterogeneity (P < 0.001,
I2 = 38.4%), which largely disappeared after stratification by
geographical region. Odds ratios in Europe, Australia, and
North America attenuated towards the null, unlike those in the
Middle East and Asia.
Conclusions No strong evidence exists to support an
association of the MTHFR 677 C→T polymorphism and
coronary heart disease in Europe, North America, or Australia.
Geographical variability may be due to higher folate intake in
North America and Europe or to publication bias. The
conclusion drawn from previous meta-analyses that folic acid,
through lowering homocysteine, has a role in prevention of
cardiovascular disease is in some doubt.
Introduction
Observational studies have consistently shown that higher
plasma homocysteine concentrations are associated with an
greater risk of coronary heart disease.1 However homocysteine-
coronary heart disease associations may be confounded (for
example, by smoking and socioeconomic position) and existing
atherosclerosis could itself increase homocysteine concentra-
tions.2 3 This last explanation (reverse causality) is supported by
evidence that the homocysteine-coronary heart disease associa-
tions derived from cohort studies are weaker than those from
case-control studies, which are, inevitably, more prone to being
biased by existing disease leading to higher homocysteine
concentrations.4
Associations between the genetic variant MTHFR 677C→T
and coronary heart disease have been reported.5 The genetic
variant is associated with elevated homocysteine concentrations
but, following the principles of mendelian randomisation,6 is not
subject to reverse causation or the confounding that exists in
observational studies of coronary heart disease risk in relation to
directly measured homocysteine concentrations. Indeed, inclu-
sion of folate—which lowers homocysteine concentrations7—in
the proposed Polypill (a combination of low dose aspirin, a statin,
three blood pressure lowering drugs, and folic acid, intended for
prevention of coronary heart disease) is supported by reference
to two meta-analyses of such genetic studies, and the evidence of
causation is said to be “compelling.”8 However, the sample sizes
needed for studies to accurately estimate the causal influence of
intermediate phenotypes such as homocysteine concentration
on disease outcomes by using common genetic variants are nec-
essarily very large,9 and publication bias (selective publication of
positive findings) is likely to be a major concern with genetic
association studies.10
In their meta-analysis, Wald et al tested for small study bias,
reporting an Egger test of P = 0.55.5 Another meta-analysis of the
association between MTHFR 677C→T and coronary heart
disease showed potential publication bias, in which non-
publication of small negative studies would lead to overestima-
tion of the strength of association between the MTHFR 677C→T
variant and coronary heart disease.11 Since the publication of
these two meta-analyses several new studies have appeared,
including one larger than any previous study.12 Adding these and
studies already published but presumably missed by the search
strategy used by previous investigators more than doubles the
number of cases available for analysis compared with the two
previous comprehensive meta-analyses.5 11 We have therefore
carried out an updated meta-analysis using a comprehensive lit-
erature search and fully investigated potential publication bias.
This work is important, as it is essential to define carefully the
evidence for inclusion of folic acid in the Polypill, which has been
strongly promoted, has been patented, and is in the process of
being manufactured.
References to included studies are on bmj.com
Cite this article as: BMJ, doi:10.1136/bmj.38611.658947.55 (published 10 October 2005)
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Methods
We identified eligible studies by searching Medline and Embase
for all publications between January 2001 and August 2004,
updating the search used in earlier meta-analyses.5 We used the
search terms “mthfr,” “methylenetetrahydrofolate reductase,”
“5,10 methylenetetrahydrofolate reductase,” “677C,” and
“C677T” in combination with “cardiovascular disease,” “ischemic
heart disease,” “coronary,” “heart disease,” “myocardial infarc-
tion,” and “angina.” We did not exclude any studies on the basis
of language. We used the outcome as defined by previous inves-
tigators of myocardial infarction or coronary artery occlusion
( > 50% of the luminal diameter).
We based unadjusted odds ratios on published genotype fre-
quencies or extracted them directly from publications where raw
data were not available. We used random effects models.
Where possible, we assessed whether the frequencies of CC,
CT, and TT genotypes among controls in individual studies were
consistent with the expected distribution (that is, in Hardy-
Weinberg equilibrium) by using the Pearson 2 test. In line with
previous work, we compared the TT genotype with the CC
genotype. In our meta-analysis of all studies, we stratified by the
geographical region in which the studies were done—Asia, Aus-
tralia, the Middle East, North America, and Europe—and gave
odds ratios by region. We quantified the extent of heterogeneity
by using I_, which represents the percentage of total variation
across studies that is attributable to heterogeneity rather than
chance.13 Where mean serum homocysteine concentrations were
given by genotype, we extracted these for all samples or for con-
trols only where values for all samples were not provided or
could not be calculated. We estimated the difference in serum
homocysteine concentrations between CC and TT genotypes by
using a random effects meta-analysis. We used meta-regression
analysis to assess whether differences in serum homocysteine
concentration affected MTHFR-disease associations. We used
Stata version 8 for all statistical analyses.
We calculated the predicted odds ratio for coronary heart
disease risk for a 5 mol/l increase and a 3 mol/l decrease in
homocysteine concentrations, for comparison with the Wald et al
meta-analysis,5 by raising the odds ratio and confidence intervals
to the power of 5/2.24 (the overall difference in mean
homocysteine between CC and TT genotypes) and to the power
of − 3/2.24.
Results
In all, we included 81 data points from 80 studies in this
meta-analysis (table 1; fig 1), with a total of 26 000 cases and
31 813 controls.We identified 24 studies that we believe fitted the
earlier reviews’ inclusion criteria,5 11 but which were not included
in either of the original meta-analyses either because they were
not identified by the original search strategies or because they
have been published since this meta-analysis. We found an over-
all random effect odds ratio for coronary artery disease compar-
ing TT with CC genotypes of 1.14 (95% confidence interval 1.05
to 1.24). Five studies showed evidence to suggest (P < 0.05) that
genotypes were not in Hardy-Weinberg equilibrium in controls.
However, exclusion of these studies made very little difference to
the overall result (odds ratio 1.15, 1.06 to 1.26). We also found
evidence that effect estimates were related to study size, suggest-
ing that small study bias, such as publication bias, may have dis-
torted the findings (Egger test P = 0.03).
We found strong evidence of between study heterogeneity
(P < 0.001, I2 = 38.4%). Stratified analysis by geographical region
removed much of the heterogeneity within Europe, North
America, Australia, and the Middle East; the random effect odds
ratio were 1.08 (0.99 to 1.18; Pheterogeneity = 0.19, I
2 = 16.1%) among
the 42 European studies, 0.93 (0.80 to 1.10; Pheterogeneity = 0.64,
I2 = 0%) among the 15 North American studies, 1.04 (0.73
to1.49; Pheterogeneity = 0.97, I
2 = 0%) among the three Australian
studies, and 2.61 (1.81 to 3.75; Pheterogeneity = 0.57, I
2 = 0%) among
Table 1 Summary findings by geographical region: odds ratios for coronary heart disease comparing TT with CC genotypes, and difference in geometric
mean serum homocysteine concentrations
Region Odds ratio (95% CI) No of cases:controls No of studies
Difference in serum homocysteine
CC-TT (95% CI)
Odds ratio (95% CI) for 5 mol/l
increase in homocysteine
Europe 1.08 (0.99 to 1.18) 17 275:21 313 41 2.03 (1.15 to 2.90) 1.21 (0.98 to 1.50)
North America 0.93 (0.80 to 1.10) 3714:3969 15 1.35 (0.32 to 2.38) 0.76 (0.44 to 1.42)
Middle East 2.61 (1.81 to 3.75) 971:1316 5 8.80 (1.23 to 16.4) 1.72 (1.12 to 4.90)
Asia 1.23 (0.94 to 1.62) 2755:4735 16 3.76 (2.29 to 5.23) 1.32 (0.92 to 1.90)
Australia 1.04 (0.73 to 1.49) 1285:480 3 – –
Overall 1.14 (1.05 to 1.24) 26 000:31 813 80 2.24 (1.55 to 2.94) 1.34 (1.12 to 1.62)
Potentially relevant studies identified and
screened for retrieval (n=264)
Studies retrieved for more detailed
evaluation (n=101)
Studies excluded: not a primary study, not
a cohort or case-control design, or not
related to heart disease (n=163)
Studies fulfilling inclusion criteria (n=85)
Studies excluded; outcomes did not fit
inclusion criteria (n=8):
 Family studies (n=2)
 No control group (n=2)
 Duplicate findings (n=4)
Studies included in meta-analysis (n=80)
Studies excluded:
 Insufficient data (n=3)
 No TT genotypes among cases (n=2)
Fig 1 Results of search strategy
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the five Middle Eastern studies (fig 2). Evidence of heterogeneity
remained between Asian studies, but this was only apparent
between Japanese studies and others and within studies done in
Japan. The random effects odds ratio for Japanese studies was
1.71 (1.23 to 2.37; Pheterogeneity = 0.01, I
2 = 62.5%); studies done in
China, Taiwan, and Korea produced homogeneous results, with
an overall odds ratio of 0.81 (0.60 to 1.10; Pheterogeneity = 0.41,
I2 = 3.0% ).
To minimise the effect of inter-laboratory variation in meas-
urement of homocysteine concentrations, we used differences in
homocysteine concentrations between TT and CC genotypes
rather than absolute homocysteine concentrations as a measure
of geographical differences in dietary folate, as differences in
homocysteine concentrations by MTHFR C677T genotype have
been shown to be greater at lower levels of folate intake and are
reduced after folate supplementation.14 We examined whether
these differences were associated with the size of effect of the
MTHFR genotype on coronary heart disease risk. Of the 20
studies that gave mean homocysteine concentrations and stand-
ard deviations by genotype, the differences ranged from − 0.8 to
11 mol/l (table 2). A random effects meta-analysis of mean dif-
ference in homocysteine concentrations between CC and TT
genotypes found an overall difference of 2.24 mol/l (95% con-
fidence interval 1.55 to 2.94). In a meta-regression analysis we
found evidence to suggest that differences in serum homo-
cysteine concentrations by genotype were associated with the
effect of genotype on coronary artery disease risk (= 0.103,
P = 0.02), although this does not take into account the
uncertainty in homocysteine differences by genotype. This
equates to an increase in the odds ratio of exponential 0.103
(0.019 to 0.186) or 1.11 (1.01 to 1.20) per 1 mol/l increase in
the difference in homocysteine concentrations between CC and
TT genotypes.
We calculated the predicted odd ratios for coronary heart
disease risk for given changes in homocysteine concentrations
by region (table 1) and compared them with the Wald et al5
meta-analysis (table 3). Findings were broadly similar for
increased odds of coronary heart disease associated with the CC
genotype and the effect of a 5 mol/l increase or a 3 mol/l
decrease in homocysteine concentration between our meta-
analysis and Wald’s.
Discussion
Do high homocysteine concentrations cause heart disease?
Our meta-analysis of 80 studies gives an estimate of a 14% (95%
confidence interval 5% to 24%) greater risk of coronary heart
disease associated with the MTHFR CC genotype. However,
because of the marked heterogeneity between studies, causal
inferences about the association between homocysteine and
coronary heart disease must be guarded. Because of the large
amount of data in our meta-analysis, an examination of the geo-
graphical variation was possible; this showed wide variation
between regions, and in European, north American, and
Australian studies no strong evidence existed to support any
effect of homocysteine on coronary heart disease risk. Only in
studies carried out in the Middle East and in Asia did any
evidence exist to support the hypothesis, and in Asia the effect
was confined to Japanese studies only.
Is regional heterogeneity due to differences in folate intake?
It has been suggested that the observed geographical differences
relate to nutritional habits, widespread use of vitamin
supplements, or fortification of breakfast cereals with folate in
North America and Europe in contrast with more unfavourable
intakes of folic acid in other regions.11 Differences in
homocysteine concentrations by MTHFR C677T genotype have
been shown to be greater at lower levels of folate intake and are
reduced after folate supplementation.14 In our meta-analysis we
found relatively modest differences in homocysteine concentra-
tions by genotype in the United States, where fortification of
foods with folate is mandatory, but larger differences in other
regions. A recent meta-analysis that used mendelian randomisa-
tion to examine the association of homocysteine with stroke
confirmed the lower mean difference between TT and CC
MTHFR C677T genotypes in homocysteine concentration for
North American but not European studies, but the numbers of
participants studied were much smaller.15 If increased folate
intake in some parts of the world does explain the heterogeneity
of the associations, folic acid as a preventive intervention would
be unlikely to have any major role to play in the regions where
there is no MTHFR-coronary heart disease association.
Regional heterogeneity and publication bias
We found that differences in homocysteine concentrations by
genotype were positively associated with the size of the effect of
genotype on risk of coronary heart disease. However, this does
not necessarily provide convincing evidence of a causal relation
between homocysteine concentrations and risk of coronary
heart disease, because the correlation of larger mean differences
and larger effects in certain regions could equally represent pub-
lication bias. The strongly positive studies reported from the
middle East and Japan could also represent publication bias,
especially given the high levels of scientific activity around
MTHFR variants. In support of this, although our meta-analysis
included too few Japanese and Middle Eastern studies to provide
sufficient power to test for small study bias, the largest Japanese
study included gave a null result (odds ratio 0.99, 0.74 to 1.32),16
and a further large Japanese study (445 cases) that could not be
included in our meta-analysis owing to insufficient data also
found a null result (P > 0.1).17 The largest Middle Eastern study
included in our meta-analysis, which contributed more than half
of the total cases for this region, gave a result that was not incom-
patible with the null hypothesis.18 A similar meta-analysis of
MTHFR and ischaemic stroke also found a greater increase in
risk among TT homozygotes in Japan compared with other
countries and regions.19 The inference that the MTHFR-disease
association is greatest in Japan because folate intake is low seems
to be incongruous with the low incidence of folic acid deficiency
and neural tube defects in Japan relative to other countries.20 21
Evidence from clinical trials
Recent trials of folate supplementation in North America,
Europe, and Australia that have examined clinical outcomes and
surrogates have been negative.22–26 These trials have largely being
done in populations with high background folate consumption
and are unlikely to resolve the question of whether folate supple-
mentation or folate fortified food could be an important
intervention in populations with “insufficient” folate consump-
tion. We await more randomised trial findings that, we hope, will
clarify the role of homocysteine in coronary heart disease and
the relevance of folate supplementation for prevention.
Limitations
Any meta-analysis has limitations, and although we invested
considerable effort in searching for published studies of genetic
associations and found considerably more than previous
meta-analyses, our estimates of effect are still likely to represent
overestimation through publication bias. Unlike randomised
controlled trials, which are becoming easier to locate, aided by
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Study  Weight
(%)
 Odds ratio
(95% CI) Odds ratio (95% CI)Asia
Zhengw1
Zhangw57
Chaow4
Jangw67
Hsuw17
Hongw59
Shiojiw49
Kimw22
Kiharaw31
Chenw50
Izumiw36
Nakaiw37
Moritaw38
Ouw40
Kouw66
Kawashiriw42
Subtotal
North America
Folsomw68
Brugadaw8
Schmitzw10
Hansonw6
Brilakisw62
Hopkins*
Verhoefw13
Maw14
Dilleyw15
Schwartzw16
Andersonw23
Christensenw26
Topolw65
Malinoww41
Paynew75
Subtotal
Middle East
Tokgozogluw33
Abu-Amerow61
Inbalw51
Magerw44
Güleçw46
Subtotal
Australia
Van Bockxmeerw18
Wilckenw20
Silberberg*
Subtotal
Favours association of
CHD with CC genotype
Favours association of
CHD with TT genotype
2.6
4.9
4.8
7.6
6.2
6.8
11.0
6.4
5.2
3.0
8.1
7.8
9.9
8.9
2.1
4.7
100.0
32.8
43.6
23.6
100.0
10.6
26.1
28.4
23.7
11.2
100.0
7.3
3.1
6.8
14.0
5.5
5.0
16.8
9.3
0.9
3.2
8.7
4.1
12.0
2.9
0.5
100.0
0.20 (0.04 to 0.93)
0.58 (0.22 to 1.53)
0.62 (0.23 to 1.65)
0.66 (0.35 to 1.22)
0.90 (0.41 to 1.98)
0.96 (0.47 to 1.95)
0.99 (0.74 to 1.32)
1.07 (0.50 to 2.28)
1.46 (0.58 to 3.66)
1.50 (0.38 to 5.98)
1.64 (0.93 to 2.91)
1.74 (0.95 to 3.18)
2.08 (1.40 to 3.11)
2.32 (1.41 to 3.80)
3.02 (0.54 to 16.72)
3.12 (1.15 to 8.48)
1.23 (0.94 to 1.62)
0.99 (0.53 to 1.85)
1.04 (0.61 to 1.80)
1.12 (0.53 to 2.35)
1.04 (0.73 to 1.49)
1.50 (0.49 to 4.59)
1.98 (0.97 to 4.04)
2.65 (1.34 to 5.25)
3.51 (1.66 to 7.41)
4.29 (1.45 to 12.70)
2.61 (1.81 to 3.75)
0.66 (0.37 to 1.19)
0.77 (0.31 to 1.89)
0.80 (0.44 to 1.47)
0.82 (0.54 to 1.26)
0.83 (0.42 to 1.62)
0.83 (0.41 to 1.69)
0.84 (0.57 to 1.24)
0.84 (0.50 to 1.41)
0.84 (0.15 to 4.68)
0.90 (0.37 to 2.19)
1.11 (0.65 to 1.91)
1.28 (0.59 to 2.81)
1.29 (0.82 to 2.05)
2.60 (1.02 to 6.65)
3.40 (0.35 to 33.40)
0.93 (0.80 to 1.10)
Europe
Chambers (Asian)w2
Verhoeffw69
Roestw71
Brulhartw5
Goracyw56
Adamsw9
Ardissinow11
Meiselw12
Girelliw7
Kadzielaw70
Rothenbacherw55
Frederiksen (cohort)w47
Tobinw48
Abbatew19
Frederiksen (case-control)w47
Vascular Biology
  Italian Study Groupw73
Pintów21
Köllingw64
Kluijtmansw24
Fernandez-Arcasw3
Meleadyw74
Fowkesw25
Kozich*
Gardemannw27
Benesw58
Spiridonovaw52
Chambers (European)w2
Tanisw53
Todescow28
Kostulasw60
Zuntarw63
Reinhardtw29
Verhoefw30
Araujow32
Malikw34
Thörgersenw35
Ferrer*
Gemmatiw72
Szczeklikw39
Raslovaw54
Gallagherw43
Ferrer-Antunesw45
Subtotal
0.44 (0.12 to 1.57)
0.56 (0.31 to 1.03)
0.66 (0.38 to 1.16)
0.69 (0.40 to 1.17)
0.69 (0.26 to 1.85)
0.80 (0.45 to 1.40)
0.81 (0.46 to 1.45)
0.82 (0.59 to 1.13)
0.86 (0.53 to 1.37)
0.87 (0.36 to 2.10)
0.88 (0.54 to 1.43)
0.96 (0.76 to 1.22)
0.97 (0.65 to 1.43)
1.03 (0.46 to 2.27)
1.04 (0.88 to 1.23)
1.06 (0.85 to 1.33)
1.06 (0.42 to 2.70)
1.07 (0.79 to 1.45)
1.21 (0.87 to 1.68)
1.22 (0.74 to 2.00)
1.25 (0.83 to 1.88)
1.28 (0.59 to 2.77)
1.28 (0.80 to 2.06)
1.30 (0.73 to 2.29)
1.30 (0.73 to 2.34)
1.31 (0.49 to 3.48)
1.32 (0.78 to 2.22)
1.34 (0.77 to 2.32)
1.35 (0.60 to 3.02)
1.35 (0.41 to 4.43)
1.37 (0.73 to 2.57)
1.38 (0.59 to 3.20)
1.42 (0.52 to 3.84)
1.49 (0.30 to 7.30)
1.52 (0.78 to 2.95)
1.58 (0.47 to 5.37)
1.63 (0.49 to 5.40)
2.11 (1.07 to 4.16)
2.17 (1.04 to 4.52)
3.13 (0.95 to 10.34)
3.27 (1.26 to 8.49)
3.68 (1.25 to 10.85)
1.08 (0.99 to 1.18)
0.5
1.9
2.2
2.4
0.8
2.1
2.1
5.2
2.9
0.9
2.7
7.8
3.9
1.2
10.7
8.2
0.9
5.8
5.1
2.7
3.7
1.2
2.9
2.1
2.0
0.8
2.4
2.2
1.1
0.5
1.8
1.0
0.7
0.3
1.6
0.5
0.5
1.5
1.3
0.5
0.8
0.6
100.0
0.1 0.2 0.5 2 5 101
Fig 2 Association between MTHFR C677T polymorphism and coronary heart disease (TT versus CC genotype). *Unpublished data taken from Klerk et al, 2002
meta-analysis
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the work of the Cochrane Collaboration, observational genetic
epidemiology has yet to develop mechanisms for producing
robust and systematic reviews of available evidence. Mechanisms
are clearly needed for sharing of data, archiving of all relevant
findings whether positive or negative, and avoiding duplication
of effort. Guidelines could be developed by building on
experience gained over the past five years in the conduct of
reviews of human genome epidemiology (HuGE).27 A further
limitation of our analysis is that we did not have individual level
data and were not able to take account of the uncertainty in dif-
ferences in mean homocysteine concentrations between people
with CC and TT genotypes in our meta-regression analysis. To
allow comparison with Wald et al,5 we did not limit the
estimation of our MTHFR-homocysteine effect to healthy
people, and the inclusion of some people with disease in this
analysis may have clouded the true effect of genotype.28
Conclusions
The results of this meta-analysis cast some doubt on the implica-
tions drawn from previous reviews that support a role for folic
acid in preventing cardiovascular disease. Ironically, enthusiasm
for such intervention comes from high income countries where
the evidence would suggest there would be little, if anything, to
gain with respect to coronary heart disease risk from increasing
folic acid intake. The growing observational evidence has impor-
tant implications for the inclusion of folic acid in any Polypill
strategy.
Table 2 Studies reporting serum homocysteine concentrations (mol/l) according to MTHFR genotype: homozygotes for the mutant allele (TT),
heterozygotes (CT), and wild type homozygotes (CC)
Study: first author
TT CT CC Difference between
TT and CCMean (SD) No Mean (SD) No Mean (SD) No
Chambers (Asian)w2 11.6 (12.2) 15 11.3 (4.5) 151 11.2 (4.2) 439 0.4
Chaow4 12.6 (6.6) 19 10.8 (4.2) 72 9.7 (4.0) 101 2.9
Tsaiw6b 10.4 (4.3) 52 9.4 (4.1) 212 9.1 (4.3) 194 1.3
Girelliw7b 20.7 112 15.5 322 14.6 221 6.1
Schmitzw10 9.1 (2.3) 14 10.6 (3.8) 46 9.9 (2.7) 67 −0.8
Meiselw12 10.3 (4.5) 177 9.7 (3.6) 421 9.4 (4.5) 265 0.9
Maw14 12.6 (4.1) 72 10.9 (5.9) 240 10.6 (5.9) 271 2
Schwartzw16 13.5 (7.0) 43 10.8 (3.9) 141 10.9 (3.8) 154 2.6
Kimw22 13.5 (6.0) 16 12.6 (3.10) 41 12.2 (3.5) 30 1.3
Kluijtmansw24 15.4 (8.2) 51 13.4 (6.3) 233 12.6 (5.7) 231 2.8
Christensenw26 12.8 (4.7) 22 11.0 (3.9) 98 10.3 (3.5) 87 2.5
Chambers (European)w2 11.7 (5.6) 72 10.5 (4.1) 286 10.3 (3.0) 296 1.4
Verhoefw30 16.9* 20 12.4* 107 11.8* 104 5.1
Tokgozogluw33 23.3 (15) 16 16.9 (9) 57 14.5 (7) 57 8.8
Nakaiw37 11.6 (5.6) 63 8.9 (4.1) 191 8.6 (3.3) 174 3
Ouw40 15.1 (6.0) 27 11.2 (1.9) 19 10.5 (3.3) 39 4.6
Malinoww41 10.3 (3.8) 25 9.4 (3.7) 128 9.1 (3.5) 89 1.2
Kawashiriw42 21.0 (11.0) 12 11.0 (3.5) 36 10.0 (4.6) 34 11
Frederiksenw47 14.7 (9.25) 342 11.7 (4.17) 1738 11.8 (4.42) 1955 2.9
Tanisw53 14.9 (5.3) 59 12.4 (3.2) 262 11.6 (2.7) 280 3.3
Raslova†w54 18.5* 14.4* 13.5* 5
Rothenbacherw55 10.2 81 8.7 336 8.4 374 1.8
Köllingw64 13.2 (5.7) 52 11.9 (4.1) 284 11.7 (4.5) 281 1.5
Jangw67 13.5 (6.79) 48 8.95 (3.65) 115 8.87 (3.77) 67 4.6
Verhoeffw69 17.6* 13.2* 12.7* 4.9
Meleadyw74 12.2* 81 9.7* 314 9.3* 352 2.9
*Geometric mean.
†Estimated from figure.
Table 3 Summary results from three meta-analyses of MTHFR C677T and
coronary heart disease
Study
Overall odds ratio
(95% CI)
5 mol/l increase in
homocysteine
3 mol/l decrease in
homocysteine
Wald et al5 1.21 (1.06 to1.39) 1.33 (1.22 to 1.46) 0.84 (0.80 to 0.89)
Klerk et al11 1.11
(1.05 to 1.28)
Not available Not available
Our meta-analysis 1.14 (1.05 to1.24) 1.34 (1.12 to 1.62) 0.84 (0.75 to 0.94)*
*Our confidence intervals are larger because we included only studies with information on
coronary heart disease in the analysis of difference in homocysteine concentration by
genotype, whereas Wald et al also included studies of deep vein thrombosis and stroke.
What is already known on this topic
The MTHFR 677C→T polymorphism is associated with
homocysteine concentration; people with TT genotype
have higher concentration than those with the CC genotype
Two recent meta-analyses reported associations between
MTHFR C677T genotype and coronary heart disease,
concluding that high homocysteine concentrations are
causally related to coronary heart disease risk
What this study adds
Since the publication of the previous meta-analyses several
more studies have been published, and the total number of
cases and controls has doubled
This meta-analysis provides no evidence of a causal relation
between homocysteine and coronary heart disease risk in
European, North American, and Australian populations
This study casts doubt on the beneficial role of lowering
homocysteine concentrations, through supplementation
with folic acid, to prevent heart disease
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